BMJ Open

Effect of intermittent fasting after ST-elevation myocardial infarction on left ventricular function: study protocol of a pilot randomised controlled trial (INTERFAST-MI)

Jochen Dutzmann ,[1] Kai Knöpp,[1] Zoe Kefalianakis,[1] Jan-Marcus Daniel,[1] Hubert Gufler,[2] Walter Wohlgemuth,[2] Florian Kahles,[3] Daniel G Sedding[1]

To cite: Dutzmann J, Knöpp K, Kefalianakis Z, *et al*. Effect of intermittent fasting after ST-elevation myocardial infarction on left ventricular function: study protocol of a pilot randomised controlled trial (INTERFAST-MI). *BMJ Open* 2022;**12**:e050067. doi:10.1136/bmjopen-2021-050067

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2021-050067).

JD and KK contributed equally.

Received 09 February 2021
Accepted 31 January 2022

[1]Department of Internal Medicine III, University Hospital Halle, Halle, Germany
[2]Department of Radiology, University Hospital Halle, Halle, Germany
[3]Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany

Correspondence to
Professor Daniel G Sedding; daniel.sedding@uk-halle.de

ABSTRACT

Introduction Preclinical studies consistently show robust disease-modifying effects of intermittent fasting in animal models of cardiovascular disease. However, the impact of intermittent fasting on cardiovascular endpoints after myocardial infarction has not been investigated in a clinical trial so far.

Methods and analysis The INTERmittent FASTing after Myocardial Infarction (INTERFAST-MI) trial is a monocentric prospective randomised controlled non-confirmatory pilot study including 48 patients with ST-segment elevation myocardial infarction. They will be randomised in a 1:1 ratio to either intermittent fasting (daily time-restricted eating; consuming food for not more than 8 hours/day, fasting for at least 16 hours/day) or to a control group without a particular diet. The follow-up time is 6 months. The prespecified primary outcome is change in left ventricular systolic function at 4 weeks from baseline to estimate effect size required to establishing sample size and power calculation for a future full-scale trial. Secondary outcomes include protocol adherence, recruitment, major adverse cardiac events, revascularisation, changes in left ventricular systolic function at 3 and 6 months, patient weight, blood pressure, and serum markers of inflammation and cardiovascular disease. Enrolment began on 1 November 2020 and is expected to conclude in December 2021.

Ethics and dissemination The trial has received ethics approval from the Medical Ethics Committee of the Martin-Luther-University Halle-Wittenberg. Results of the study will be submitted for publication in a peer-reviewed journal and presented at scientific conferences.

Trial registration number DRKS00021784.

Strengths and limitations of this study

- This is the first randomised controlled trial assessing the effect of intermittent fasting on cardiac function.
- Design of this pilot study facilitates the evaluation of feasibility and safety of the protocol and calculation of the sample size for a future multicentre trial to assess major adverse cardiac events as primary endpoints.
- Scheduling of the exact fasting periods is left up to each patient's choice, thereby improving patient's compliance and translation into clinical routine, but disguising potential effects by lack of standardisation.
- Statistical power of 60% was defined to be adequate for this non-confirmatory pilot study, but led to a small calculated sample size and might limit reliable interpretation of the results.
- Nature of the study intervention precludes any possibility of blinding.

INTRODUCTION

Long-term caloric restriction has been shown to robustly effect ageing and lifespan extension in mice and non-human primates and to exhibit numerous health-related effects in clinical trials.[1–3] It sets off an evolutionary conserved, adaptive cell response in improving the efficacy of glucose metabolism, cellular stress resistance as well as DNA repair mechanisms, and suppresses inflammatory processes. In particular, periodic flipping between fasting and non-fasting phases ('metabolic switch') improves resilience and long-term disease resistance.[2]

Preclinical animal studies illustrate the therapeutic effects of intermittent fasting, for example, in adiposity, diabetes mellitus, cardiovascular, neoplastic and neurodegenerative diseases.[4] Clinical trials provide conclusive and robust human data for the beneficial effects of fasting in adiposity, insulin resistance, dyslipidaemia, arterial hypertension and inflammation.[5] In humans, the health benefits of intermittent fasting do not seem to be solely attributed to a reduction in caloric intake. In a randomised controlled British monocentre trial, 107 overweight

women were assigned to either an intermittent fasting regime (with very low calorie diet for 2 days/week and no restriction on the other 5 days/week) or continuous reduction in daily caloric intake. Women assigned to either group lost the same amount of body weight, but those randomised to the intermittent fasting regime had a greater increase in insulin sensitivity and a larger reduction in waist circumference.[6]

Fasting improves numerous indicators of cardiovascular health including blood pressure, resting heart rate, serum levels of high-density lipoprotein (HDL), low-density lipoprotein (LDL), cholesterol, and triglycerides as well as serum levels of glucose and insulin and insulin sensitivity.[7–10] In animal studies, the improvements in cardiovascular health indicators show up at 2–4 weeks after the start of intermittent fasting. They dissipated over weeks after continuation of an ad libitum diet.[11]

These cardioprotective effects as well as the above-mentioned cellular mechanisms of intermittent fasting are crucial for myocardial healing, myocardial and vascular regeneration, as well as secondary prevention after myocardial infarction (MI).[12]

Two groups from the USA and Brazil independently investigated the effect of intermittent fasting on MI-induced myocardial remodelling in rats.[13 14] Both groups, Ahmet *et al* and Okoshi *et al* could provide robust evidence for beneficial effects of intermittent fasting in post-MI cardiac remodelling including better left ventricular (LV) function, a reduction in LV dilation and a reduction in cardiomyocyte hypertrophy. Okoshi *et al* confirmed these effects even in rats, in which intermittent fasting was initiated after MI.[14]

However, clinical trials to validate these experimental data in human disease and to finally translate it to clinical practice are still needed. We designed the INTERmittent FASTing in Myocardial Infarction (INTERFAST-MI) trial to assess feasibility of a future multicentre trial. In detail, we aim to establish sample size and power calculation required for a full-scale study. We furthermore propose to evaluate the financial, technical, administrative, and logistic feasibility, especially including issues of data collection and protocol adherence.

METHODS AND ANALYSIS

Study design

INTERFAST-MI is a prospective randomised controlled non-blinded single-centre investigator-initiated pilot trial. The study is carried out in the Department of Cardiology, Angiology and Intensive Care Medicine of the Martin-Luther-University Halle-Wittenberg. The study is sequentially conducted as follows: enrolment according to prespecified inclusion and exclusion criteria, randomisation and follow-up for 6 months with follow-up visits at 4 weeks, 3 months and 6 months, voluntary cross-over at 3 months, and assessment (figure 1). The study is designed to provide important parameters, which can be used to evaluate the feasibility and safety of the protocol and calculate the sample size for a future multicentre trial. The study protocol was designed according to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trial) guideline,[15] the reporting checklist is included in the online supplemental material. INTERFAST-MI has been registered at the German Clinical Trials Register (DRKS00021784, the trial registration dataset is also included in the online supplemental material).

Study period

The study started in November 2020 and will end 6 months after recruitment of the last participant, expected in the mid of the year 2022.

Participants and eligibility

Male or female patients older than 18 years with ST-segment elevation myocardial infarction (STEMI) or equivalent are eligible for screening according to the inclusion and exclusion criteria.

Inclusion criteria

The inclusion criteria are as follows: STEMI or equivalent (ie, De Winter's sign suggesting proximal left anterior



Figure 1 Study design. Following enrolment according to prespecified inclusion and exclusion criteria, randomisation and baseline evaluation are followed by visits at 4 weeks, 3 months and 6 months. At 3 months, voluntary cross-over is provided to the participants. PCI, percutaneous coronary intervention.

descending artery (LAD) lesion, new left bundle branch block (LBBB), or identification of STEMI by modified Sgarbossa's criteria in the setting of LBBB or pacemaker), written informed consent and age older than 18 years.

Exclusion criteria

Patients are excluded, if they have any of the following: concurrent participation in other interventional studies, non-MRI compliant devices, severe kidney failure (glomerular filtration rate (GFR) <30 mL/min), severe claustrophobia, antidiabetic therapy with sulfonyl urea or insulin, pregnancy, relationship of employment or other dependencies to the executing department.

Randomisation procedure and treatment allocation

Randomisation takes place within 48 hours after the revascularisation procedure. The allocation ratio is 1:1 to the study groups 'ad libitum diet' or 'intermittent fasting'. We performed blocked randomisation and generated blocks with a size of four by http://www.randomizer.org.[16] Matching for comorbidities or concurrent medication is not planned.

Study intervention

Participants randomised to the intervention arm are requested to perform intermittent fasting, that is, ad libitum diet for not more than 8 hours/day (eg, from 12:00 to 20:00) alternately with fasting for at least 16 hours/day (eg, 20:00 to 12:00) for 3 months from baseline. Scheduling of the exact fasting periods is free of each patient's choice after discharge from the hospital and can be adjusted to individual circumstances, as long as the minimum durations of the fasting periods are maintained. Intake of water and medication is allowed during fasting periods. The study arm 'ad libitum diet' is the control group without any further intervention. After 3 months from baseline, participants can cross over to the other study arm for further 3 months, if they want to, or proceed in the study arm initially randomised to.

Study outcomes

Primary outcome

The primary outcome is the change in LV systolic function as assessed by left ventricular ejection fraction (LVEF) from baseline after 4 weeks of intermittent fasting. LVEF is determined by echocardiography with the biplane Simpson's method by not more than two different physicians with expertise in echocardiography and who are blinded to treatment allocation.[17] This primary outcome has been chosen to estimate effect size required to establishing sample size and power calculation for a future full-scale trial.

Secondary outcomes

Secondary feasibility outcomes are protocol adherence and recruitment. Further secondary outcomes are death or hospitalisation due to cardiovascular events, all-cause mortality, change of LVEF from baseline after 3 and 6 months, further echocardiographic parameters (ie, wall motion, LV diastolic function and others), further MRI parameters (ie, presence of oedema, size of a myocardial scar, and others), change of body weight and blood pressure, medication, de novo diagnosis of comorbidities (especially diabetes mellitus), change of health-related quality of life (assessed by the HeartQoL questionnaire[18]), change of several laboratory parameters (ie, NT-proBNP, creatinine, fasting insulin, fasting blood glucose, HbA1c, complete blood count including white blood differential, inflammation parameters including C-reactive protein, interleukin (IL)-1, IL-6, cholesterol, LDL, HDL, triglycerides), gene expression pattern and cellular function of circulating immune cells, and DNA methylation/ageing patterns of circulating cells ('epigenetic clock').

Follow-up protocol

Within 48 hours after MI, patients are randomised and transthoracic echocardiography and cardiac MRI are performed. Cardiac biomarkers (ie, troponin, total creatine kinase and its MB isoform) are measured before starting the protocol to assess infarct injury before starting the protocol. Blood is collected at 20:00 at the day of study inclusion (pre-fasting), at 12:00 at the day after study inclusion (pre-ad libitum), and at 15:00 at the day after study inclusion (refeeding). Furthermore, comorbidities as well as medication at admission and discharge are recorded and the HeartQoL questionnaire is performed. At 4 weeks, 3 months and 6 months after inclusion, fasting blood is collected at 12:00, transthoracic echocardiography and the Heart QoL are performed, and medication as well as comorbidities are recorded. At 4 weeks, an additional cardiac MRI is performed. The complete schedule of enrolment is included in the online supplemental material.

All patients are encouraged to keep a journal and note their exact times of fasting and eating as well as once daily their body weight and blood pressure through the complete duration of the study. This journal is regularly checked by study personnel on follow-up visits. A sphygmomanometer is provided to the participants for the duration of the study.

A continuous glucose measurement (FreeStyle *Libre* 2, Abbott, Germany) to record the participant's adherence to the intervention and to compare blood glucose and nutrition profiles between the study groups is regarded as a voluntary option for the participants.

Harms

For patients undergoing intermittent fasting, severe events are conceivable only for those with diabetes mellitus treated with insulin or sulfonyl urea. These patients are thus excluded from participation. There are few side effects for a cardiac MRI, if any. Allergic reactions to the contrast agent are rare. Serious reactions in patients with renal dysfunction are reported. Patients with severe kidney failure are thus also excluded. Less severe adverse effects (ie, dizziness, falls, migraine headaches,

etc) are not explicitly tracked, but are implicated in the HeartQoL questionnaire.

Data collection and management

Patient's data collection and management is initiated after obtaining and documenting informed consent. Patient's data and samples are pseudonymised. Personal information is kept in a locked storage unit.

The data collected at baseline and follow-up visits are filled in an electronic case report form (eCRF) using the web-tool CastorEDC. Original medical records and informed consents are archived in the study centre. The data are entered independently into the database by two researchers and are checked separately by different trained researchers.

Sample size

Sample size was calculated based on published data of Bøtker *et al*,[19] the TOPCARE-AMI trial[20] and the BOOST-2 trial.[21] For the control group, we thus expected a mean LVEF of 50.6%±7% at 30 days,[19] a mean LVEF of 51.6%±10% at 4 months,[20] and a mean LVEF of 50.4%±7% at 6 months after MI.[21] A ≥5% absolute increase in LVEF was arbitrarily chosen to represent an improvement in myocardial function, that is, 55.6% at 30 days after MI.

INTERFAST-MI was designed as a non-confirmatory exploratory trial. The statistical power was thus set to 0.6 and the significance level was set to 0.05. Minimum sample size for a two-sided t-test calculated on this basis was 21 for each study group. Considering a dropout rate of 10%, we aim to randomise 24 patients to each study group.

Statistical methods

The intention-to-treat analysis set will be used as the principal analysis for efficacy analyses. All participants who have begun treatment will be included irrespective of their protocol adherence. Patients who complete at least 4 weeks of the study and comply well with the study protocol without major protocol violations will constitute the per-protocol set. The per-protocol analysis will be used as the secondary analysis for efficacy analyses. Missing data will be handled using the last observation carried forward method. Analysis of covariance will be used to analyse the change from baseline in primary and secondary outcomes adjusted for baseline values and treatment assignment. A two-tailed $p<0.05$ will be used as the cut-off for statistical significance. All statistical analyses will be performed using GraphPad Prism (V.8.4).

Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting or dissemination plans of our research.

ETHICS AND DISSEMINATION

This study will be performed following the principles of the Declaration of Helsinki. All patients must provide written informed consent before undergoing any study-related procedures. The study protocol has been approved by the Medical Ethics Committee of the Martin-Luther-University Halle-Wittenberg (ref. no. 2020-118). If any significant changes must be made to the protocol, a draft of the new version will be submitted for approval. The results of the trial will be published in an appropriate journal and communicated to the academic community at scientific conferences.

DISCUSSION

INTERFAST-MI is the first randomised controlled trial investigating the effects of intermittent fasting on cardiac function after MI. It has been designed as a pilot trial to evaluate feasibility and safety of the protocol and calculation of the sample size for a future multicentre trial to assess major adverse cardiac events as primary endpoints. It has some advantages and limitations.

Intermittent fasting is the chosen fasting regime in this trial due to the additional advantages in contrast to caloric restriction. *Time-restricted eating* is the chosen type of intermittent fasting in this trial to improve the patient's adherence to the intervention. Choice of this fasting regime as well as the patient's privilege to schedule their fasting periods on their own may not only increase the patient's compliance to the study intervention but also facilitate the translation into real-world clinical practice. However, it might disguise potential effects of intermittent fasting by the lack of standardisation.

Nature of the study intervention precludes any possibility of blinding. Thus, experimental biases that arise from a participants' expectations, observer's effects on the participants, as well as observer's biases could not fully excluded. Patient's awareness of their allocation status might impact especially the assessment of the secondary outcome measure health-related quality of life.

The primary endpoint of the study is change in LVEF to establish sample size and power calculation required for a full-scale study planned to investigate the hypothesis, that intermittent fasting might improve STEMI-related heart failure. Acute MI might cover up undiagnosed pre-existing heart failure with reduced ejection fraction (HFrEF). Patients with already diagnosed HFrEF might experience STEMI-related worsening of their cardiac function as other patients do and are hypothesised to benefit from intermittent fasting in a similar way. Incident diagnosis of HFrEF has thus not been included in the secondary outcomes and exclusion criteria and change in LVEF was chosen instead of arithmetic mean or median LVEF values. However, subanalyses of patient groups with certain LVEF margins (eg, <40%, 40%–50%, >50%) could be useful for the design of a future large trial.

Finally, a statistical power of 60% was assumed to be sufficient to evaluate protocol feasibility and safety of this non-confirmatory trial and to allow study conduction in an accessible manner. Nevertheless, it led to a small

calculated sample size and might limit reliable interpretation of the results.

Twitter Jochen Dutzmann @jochen_dutzmann

Acknowledgements The authors would like to thank Andreas Wienke for statistical consulting and Kathrin Ludwig, Julia Mühlhaus and Johanna Rossa for their support in study initiation and conduction.

Contributors JD and DGS conceived the trial idea and generated the original draft of the manuscript. All authors contributed to the final version. JD, KK, FK and DGS drafted the trial protocol. ZK and JMD contributed to the final version. HG and WW provided expert advice in the design of the study. All authors approved the final version for submission.

Funding This work is supported by the German Heart Research Foundation, grant number (F/47/20).

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

ORCID iD

Jochen Dutzmann http://orcid.org/0000-0003-1406-2221

REFERENCES

1 Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. *Science* 1996;273:59–63.
2 de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. *N Engl J Med* 2019;381:2541–51.
3 Longo VD, Panda S. Fasting, circadian rhythms, and Time-Restricted feeding in healthy lifespan. *Cell Metab* 2016;23:1048–59.
4 Di Francesco A, Di Germanio C, Bernier M. A time to fast. Science (80-) 2018;362:770–5. Available: http://science.sciencemag.org/ [Accessed 24 Feb 2020].
5 Redman LM, Smith SR, Burton JH, *et al*. Metabolic slowing and reduced oxidative damage with sustained caloric restriction support the rate of living and oxidative damage theories of aging. *Cell Metab* 2018;27:805–15.
6 Harvie MN, Pegington M, Mattson MP, *et al*. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. *Int J Obes* 2011;35:714–27.
7 Wan R, Camandola S, Mattson MP. Intermittent food deprivation improves cardiovascular and neuroendocrine responses to stress in rats. *J Nutr* 2003;133:1921–9.
8 Lefevre M, Redman LM, Heilbronn LK, *et al*. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. *Atherosclerosis* 2009;203:206–13.
9 Most J, Gilmore LA, Smith SR, *et al*. Significant improvement in cardiometabolic health in healthy nonobese individuals during caloric restriction-induced weight loss and weight loss maintenance. *Am J Physiol Endocrinol Metab* 2018;314:E396–405.
10 Fontana L, Meyer TE, Klein S, *et al*. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. *Proc Natl Acad Sci U S A* 2004;101:6659–63.
11 Mager DE, Wan R, Brown M, *et al*. Caloric restriction and intermittent fasting alter spectral measures of heart rate and blood pressure variability in rats. *Faseb J* 2006;20:631–7.
12 Bhatt AS, Ambrosy AP, Velazquez EJ. Adverse remodeling and reverse remodeling after myocardial infarction. *Curr Cardiol Rep* 2017;19:71.
13 Ahmet I, Wan R, Mattson MP, *et al*. Cardioprotection by intermittent fasting in rats. *Circulation* 2005;112:3115–21.
14 Okoshi K, Cezar MDM, Polin MAM, *et al*. Influence of intermittent fasting on myocardial infarction-induced cardiac remodeling. *BMC Cardiovasc Disord* 2019;19:1–9.
15 Chan A-W, Tetzlaff JM, Gøtzsche PC, *et al*. Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ* 2013;346:e7586.
16 Urbaniak GC, Plous S. *Research randomizer (version 4.0)[computer software]*, 2013.
17 Schiller NB, Acquatella H, Ports TA, *et al*. Left ventricular volume from paired biplane two-dimensional echocardiography. *Circulation* 1979;60:547–55.
18 Oldridge N, Höfer S, McGee H, *et al*. The HeartQoL: Part II. validation of a new core health-related quality of life questionnaire for patients with ischemic heart disease. *Eur J Prev Cardiol* 2014;21:98–106.
19 Bøtker HE, Kharbanda R, Schmidt MR, *et al*. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. *Lancet* 2010;375:727–34.
20 Assmus B, Schächinger V, Teupe C, *et al*. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). *Circulation* 2002;106:3009–17.
21 Wollert KC, Meyer GP, Müller-Ehmsen J, *et al*. Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. *Eur Heart J* 2017;38:2936–43.

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2,6
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	Suppl.
Protocol version	#3	Date and version identifier	Suppl.
Funding	#4	Sources and types of financial, material, and other support	10
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1, 10
Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	1
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	10
Roles and responsibilities: committees	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	n/a

Introduction			
Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4,5
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	4,5,7
Objectives	#7	Specific objectives or hypotheses	5
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	6
Methods: Participants, interventions, and outcomes			
Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6
Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6
Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	7
Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	7
Interventions: adherance	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug	8

		tablet return; laboratory tests)	
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	7, 8
Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	6, 8
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	9
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target size	n/a
Methods: Assignment of interventions (for controlled trials)			
Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	6,7
Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	6,7

Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	6,7
Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	n/a
Blinding (masking): emergency unblinding	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a
Methods: Data collection, management, and analysis			
Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	8, 9
Data collection plan: retention	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	7, 8
Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	8, 9
Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	9
Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	n/a

Statistics: analysis population and missing data	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	n/a
Methods: Monitoring			
Data monitoring: formal committee	#21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	n/a
Data monitoring: interim analysis	#21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a
Harms	#22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	8
Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
Ethics and dissemination			
Research ethics approval	#24	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	10
Protocol amendments	#25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	10
Consent or assent	#26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	10
Consent or assent: ancillary studies	#26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary	n/a

		studies, if applicable	
Confidentiality	#27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	8, 9
Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	10
Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	n/a
Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	10
Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Appendices			
Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	Supp.
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

Trial Registration Data Set

Data category	Information
Primary registry and trial identifying number	German Clinical Trials Register DRKS00021784
Date of registration in primary registry	24 September, 2020
Secondary identifying numbers	Universal Trial Number (UTN): U1111-1258-5317
Source(s) of monetary or material support	University Hospital of Halle (Saale), Germany
Primary sponsor	University Hospital of Halle (Saale), Germany
Secondary sponsor(s)	German Heart Research Foundation
Contact for public queries	Dr. Jochen Dutzmann, +49(0)345/557-2457
Contact for scientific queries	Dr. Jochen Dutzmann University Hospital of Halle (Saale), Germany
Public title	Intermittent fasting after ST-elevation myocardial infarction to improve left ventricular function
Scientific title	Intermittent fasting after ST-elevation myocardial infarction to improve left ventricular function (INTERFAST-MI): a pilot randomized controlled trial
Countries of recruitment	Germany
Health condition(s) or problem(s) studied	ST-elevation myocardial infarction
Intervention(s)	Intermittent Fasting (time-restricted feeding; at least 16 hours fasting, not more than 8 hours unrestricted diet) for three months; then voluntary continuation of intermittent fasting or cross-over for three more months
	Control (no specific dietary restrictions) for three months, the voluntary cross-over or three more months
Key inclusion and exclusion criteria	Ages eligible for study: ≥18 years Sexes eligible for study: both Accepts healthy volunteers: no
	Inclusion criteria: written informed consent, ST-elevation myocardial infarction (or equivalent)

Data category	Information
	Exclusion criteria: missing informed consent, participation in other clinical trials, patients with cardiac devices not approved for MRI scanning, kidney failure (GFR <30 ml/min), claustrophobia, antidiabetic therapy with sulfonylurea, pregnancy, employees of the study center
Study type	Interventional
	Allocation: randomized intervention model. Parallel assignment masking: no masking
	Primary purpose: prevention
	Pilot
Date of first enrolment	November 2020
Target sample size	48
Recruitment status	Recruiting
Primary outcome(s)	Left ventricular myocardial function at four weeks after randomization (evaluated by echocardiography)
Key secondary outcomes	- all-cause hospitalization - hospitalization from cardiovascular cause - all-cause death - death from cardiovascular cause - myocardial infarction - revascularisation - stroke - patient weight - blood pressure - medication - comorbidities - left ventricular function at three and six months after randomization - further characterization of myocardial function evaluated by echocardiography (i.e. Kinetikstörungen, LVEDP, E/e‘) - myocardial scar and edema (evaluated by cardiac MRI) - clinical chemistry and hematology (hGH, adiponectine, NT-proBNP, creatinine, fasting insulin, fasting blood glucose, HbA1c, blood count, IL-1, IL-6, C-reactive protein, homocysteine, cholesterine, LDL, HDL, triglycerides) - Peripheral Blood Mononuclear Cells

Data category	Information
	- DNA-Methylation of circulating cells („epigenetic clock“) Follow-up: 6 months. Study visits at regular ambulatory visits at 4 weeks, 3 months, and 6 months

Schedule of enrolment, interventions, and assessments according to the SPIRIT recommendations.

	STUDY PERIOD						
	Enrolment	Baseline			Follow-up		
TIMEPOINT	*0*	*day 0 8 p.m.*	*day 1 12 p.m.*	*day1 3 p.m.*	*4 we 12 p.m.*	*3 mo 12 p.m.*	*6 mo 12 p.m.*
ENROLMENT:							
Eligibility screen	X						
Informed consent	X						
Randomization	X						
INTERVENTIONS:							
Intermittent fasting (8/16)			♦—	—	—	—	—♦
Ad libitum diet			♦—	—	—	—	—♦
Voluntary cross-over						X	
ASSESSMENTS:							
Height	X						
Daily weight		♦—	—	—	—	—	—♦
Daily blood pressure		♦—	—	—	—	—	—♦
Continuous blood glucose		♦—	—	—	—	—	—♦
Heart QoL	X				X	X	X
Medication	X			X	X	X	X
Co-Morbidities				X	X	X	X
Echocardiography			X		X	X	X
Cardiac MRI			X		X		
DNA methylation			X		X	X	X

Circulating immune cells		X	X	X	X	X	X
Complete blood count		X	X	X	X	X	X
Interleukin-6		X	X	X	X	X	X
C-reactive protein		X	X	X	X	X	X
TSH, fT3, fT4		X			X	X	X
Albumin, prealbumin		X			X	X	X
Ferritin, transferrin		X			X	X	X
Urea acid		X			X	X	X
NT-proBNP		X	X	X	X	X	X
CK, CK-MB, Troponin T		X	X	X	X	X	X
creatinine		X			X	X	X
HbA1c		X			X	X	X
Cholesterol, LDL, HDL, triglycerides		X			X	X	X
Fasting glucose			X		X	X	X
Fasting insulin			X		X	X	X